IMI 10th Anniversary Scientific Symposium

Agenda
Day 1
22.10.2018
22.10.18

08:30 – 09:00 Registration & welcome coffee

09:00 – 10:00 Opening session

Pierre Meulien, Executive Director, IMI
Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee, UCB
Jonathan Knowles, Professor, Founding Chairman of IMI Board

10:00 – 11:00 Stratification towards personalised medicines

10:00 – 10:15 Setting the scene
- Pierre Meulien, Executive Director, IMI

10:15 – 11:00 Presentation of key achievements from IMI projects
- “Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Mechanisms”
  AETIONOMY, Fröhlich Holger, UCB
- “Quantitative PET Imaging - From Research to Clinical Use”
  AMYPAD, Heeman Fiona, VU University medical centre
- “Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium”
  DIRECT, Koivula Robert, University of Oxford

11:00 – 11:30 Coffee break

11:30 – 12:15 Presentation of key achievements from IMI projects
- “Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study”
  EPAD, Ingala Silvia, VU Medical Center
- “The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery”
  EU-AIMS, Stefan Holiga, F. Hoffmann-La Roche & Loth Eva, King’s College London
- “Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain”
  EUROPAIN, Vollert Jan, Imperial College London
“Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors”
Onco Track, Risch Thomas, Max Planck Institute for Molecular Genetics and Schütte Moritz, Alacris Theranostics GmbH

“Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression”
PRECISESADS, Toro Daniel, GENYO

12:15 – 13:30 Lunch

13:30 – 14:00 Presentation of key achievements from IMI projects
- “Federating clinical data for biomedical research in type 2 diabetes”
  RHAPSODY, Sparso Thomas, Novo Nordisk
- “Building handprints of complex diseases – severe asthma as a proof of concept”
  U-BIOPRED and eTRIKS, De Meulder Bertrand, European Institute for Systems Biology and Medicine

14:00 – 14:30 Panel discussion:
- Pamela Tenaerts, Executive Director, Clinical Trial Transformation Initiative
- Raj Long, Senior Regulatory Officer for Integrated Development in Global Health, Bill & Melinda Gates Foundation
- Martin Hofmann-Apitius, Head of the Department of Bioinformatics, Fraunhofer SCAI
- Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

14:30 – 15:00 Coffee break

15:00 – 17:15 Patient centric approaches in drug development

15:00 – 15:15 Setting the scene
- Virginie Hivert, Therapeutic Development Director, EURORDIS

15:15 – 16:45 Presentation of key achievements from IMI projects
- “Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients”
  APPROACH, Hussaarts Leonie, Lygature & Jane Taylor
- “Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines”
  EUPATI, Bereczky Tamás, Eupati
- “Driving the use of Real World Evidence in healthcare decision making”
  GETREAL, Makady Amr, Zorginstituut Nederland
“When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations”
PREFER, Chiara Whichello and Eline van Overbeeke, KU Leuven

“From development to labelling claim”
PRO-active, Demeyer Heleen, Uz Gasthuisberg

“Baseline characteristics of participants of the SPRINTT randomised clinical trial”
SPRINTT, Riccardo Calvani, Università Cattolica del Sacro Cuore

16:45 – 17:15 Panel discussion:
- Virginie Hivert, Therapeutic Development Director, EURORDIS
- Mary Baker, President, European Brain Council
- Fernand Sauer, Member, Académie National de Pharmacie
- Olivier Arnaud, Senior Director, European Research JDRF

17:15 – 19:15 Poster session

18:00 – 22:00 Networking cocktail
# Agenda
## Day 2
### 23.10.18

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:00</td>
<td>Registration &amp; welcome coffee</td>
</tr>
<tr>
<td>09:00 – 09:15</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:00 – 09:15</td>
<td>Pierre Meulien, Executive Director, IMI</td>
</tr>
<tr>
<td>09:15 – 11:15</td>
<td>Enablers for discovery and development of new drugs</td>
</tr>
<tr>
<td>09:15 – 09:30</td>
<td>Setting the scene</td>
</tr>
<tr>
<td></td>
<td>Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen</td>
</tr>
<tr>
<td>09:30 – 11:15</td>
<td>Presentation of key achievements from IMI projects</td>
</tr>
<tr>
<td></td>
<td>“An iPSC technology development collaboration – a critical component to enable ADAPTED” ADAPTED, Peter Reinhardt, AbbVie &amp; Benjamin Schmid, Bioneer</td>
</tr>
<tr>
<td></td>
<td>“Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets” COMPACT, Thanki Kaushik, University of Copenhagen</td>
</tr>
<tr>
<td></td>
<td>“Supporting stem cell research with modern data management technologies” EBISC, Seltmann Stefanie, Charité Berlin</td>
</tr>
<tr>
<td></td>
<td>“EMIF Catalogue – the bridge between data custodians and biomedical researchers” EMIF, Trifan Alina, University of Aveiro</td>
</tr>
<tr>
<td></td>
<td>“HARMONY Platform: using Big Data to fight blood cancers” HARMONY, Abáigar-Alvarado Maria, Institute of Biomedical Research of Salamanca</td>
</tr>
<tr>
<td></td>
<td>“Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavailability: case example with posaconazole” ORBITO, Bart Hens, KU Leuven</td>
</tr>
<tr>
<td></td>
<td>“Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol” RADAR-CNS, Matcham Faith, King’s College London</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
11:45 – 12:15  Panel discussion:
  ▪ Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen
  ▪ Stefan Jaroch, Head External Innovation Technologies, Global External Innovation & Alliances bei, Bayer Pharma AG
  ▪ Magali Haas, CEO & President, Cohen Veterans Bioscience
  ▪ Heiko Zimmermann, Head of Institute, Fraunhofer-Institut für Biomedizinische Technik IBMT
  ▪ Hans-Georg Eichler, Senior medical officer, European Medicines Agency

12:15 – 13:30  Lunch

13:30 – 15:30  Collaborating to fight infections

13:30 – 13:45  Setting the scene
  ▪ Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline

13:45 – 15:00  Presentation of key achievements from IMI projects
  ▪ “EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriaceae (CRE) along Europe. Inside COMBACTE network; global information for a global problem”
    COMBACTE-CARE, Paniagua Maria, Hospital Universitario Virgen Macarena
  ▪ “A new European network for influenza vaccine effectiveness studies”
    DRIVE, Turunen Topi, FISABIO
  ▪ “Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone”
    EbolaMoDRAD, Colavita Francesca, INMI
  ▪ “Modelling the humoral immune response to Ebola vaccine”
    EBOVAC1, Balelli Irene, Inserm
  ▪ “Highly potent heavy chain only antibodies protect against MERS-CoV infection”
    ZAPI, Okba Nisreen, Erasmus Medical Center

15:00 – 15:30  Panel discussion:
  ▪ Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline
  ▪ Raj Long, Senior Regulatory Officer for Integrated Development in Global Health, Bill & Melinda Gates Foundation
  ▪ Seamus O’Brien, R&D Director, Global Antibiotic Research and Development Partnership (GARDP)
  ▪ Isabelle Bekeredjian-Ding, Head of Department bei, Paul-Ehrlich-Institut
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 – 16:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>Closing &amp; Prize ceremony</td>
</tr>
</tbody>
</table>
New targets, tools and pathways

1. “Support Translation Research with High Quality Data and Interactive Visual-analytics”
   eTRIKS, Rege Kavita, University of Luxembourg

2. “Developing a robust evidence base on RSV disease and economic burden using a multidisciplinary approach”
   RESCEU, Reeves Rachel, the University of Edinburgh

3. “AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design”
   AMYPAD, Altomare Daniele, IRCCS Fatebenefratelli

4. “Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data”
   TransQST, Gunev Emre, GRIB - IMIM / UPF

5. “Stroke Risk, Bleeding Risk and Anticoagulation in Hospital EHRs”
   Big data @ heart, Bean Daniel, King’s College London & HDR UK

6. “DPP6 as a new biomarker suitable for human islet in vivo imaging”
   INNODIA, Demine Stéphane, ULB Center for Diabetes Research

7. “Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology”
   PRISM, Jongs Niels, Rijksuniversiteit Groningen

8. “Drug Evaluation in Guinea Pig Model”
   PreDiCT TB, Lanni Faye, Public Health England

   APPROACH, Van Helvoort Eefje, University Medical Centre Utrecht

10. “In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety”
    TRISTAN, Mahmutovic Persson Irma, Lund University

11. “RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers”
    ITCC-P4, Jäger Natalie, DKFZ and KiTZ, Heidelberg

12. “Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours”
    ITCC-P4, Brabetz Sebastian, Hopp Children’s Cancer Center at the NCT Heidelberg (KITZ)
13- “Candidate genes and pathways from ADAPTED Stage I integrative analysis”
ADAPTED, Madrid Márquez Laura, CAEBi Bioinformatica

14- “Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study”
EMIF-AD, Bos Isabelle, Maastricht University

15- “Data analytics and bioinformatics to successfully define asthma subphenotypes”
U-BIOPRED, Pavlidis Stelios, Data Science Institute, Imperial College London

16- “Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist”
K4DD, Sliedrecht Tale, Lygature

17- “Developing a mechanism-based taxonomy of Alzheimer’s and Parkinson’s disease”
AETIONOMY, Golriz Khatami Sepehr, Fraunhofer SCAI

18- “Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis”
OncoTrack, Azimi Alireza, Uppsala University

19- “Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling”
NGN-PET, Rutigliano Lucia, Axxam

20- “A new way to monitor Multiple Sclerosis”
RADAR-CNS, Martinis Matteo, San Raffaele Hospital

21- “Discovery of the role of the ELOVL2/docosahexaenoic acid axis in the regulation of insulin secretion and survival of rodent and human pancreatic beta cells”
IMIDIA, Bellini Lara, Université Paris Diderot

22- “Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study”
DIRECT, Frau Francesca, Sanofi

23- “Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity”
VAC2VAC, Etna Marilena Paola, istituto Superiore di Sanità

24- “Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues”
ZAPI, Wichgers Schreur Paul, Wageningen Bioveterinary Research

25- “Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa”
COMBACTE-MAGNET, Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges

26- “Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin”
COMBACTE-NET, Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges
27- “Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia”
   RAPP-ID, Jongers Bart, University of Antwerp

28- “Laboratory Analysis workflows within the ASPIRE-ICU study”
   COMBACTE-NET and COMBACTE-MAGNET, Timbermont Leen, University of Antwerp

29- “New bio-informatic approach for the analysis of flow cytometry data”
   PRECIESADS, Le Lann Lucas, University of Brest

30- “Zebrafish Proteinopathy Models for Target Validation”
   IMPrIND, Hubbard Jeffrey, Institut de Recherches Servier

31- “New candidate genes in insulin target tissues: Elolv2 as a protective enzyme against glycaemic deterioration?”
   RHAPSODY, Lallement Justine, Université Paris Diderot

32- “Integration of models of drug-induced liver injury for risk assessment”
   Trans-QST and MIP-DILI, Sison-Young Rowena, University of Liverpool

33- “Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development”
   ELF, Pravin Patil, University Of Groningen

34- “Developing human cellular phenotypic assays for pain”
   StemBANCC, Chintawar Satyan, University of Oxford

35- “Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells”
   OncoTrack, Regan Joseph, Charité - Universitätsmedizin Berlin

36- “A validated genetics-led system ‘Pi’ enables drug target discovery for immune traits”
   ULTRA-DD, Fang Hai, University Of Oxford

37- “Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine”
   EBOVAC 1 and 2, Bockstal Viki, Janssen Vaccines & Prevention

38- “A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms”
   PERISCOPE, de Graaf Hans, University of Southampton

39- “Translational Safety Assessment in Pharma”
   eTRANSAFE, Ruud Bueters, Janssen

40- “In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms”
   iABC, Diez-Aguilar Maria, Hospital Universitario Ramón y Cajal-IRyCIS

41- “Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease”
   IMPRIND, Delay Charlotte, Janssen Pharmaceuticals
42- “Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia”
EMIF-AD, Jansen Olin, Maastricht University

From concept to trial

43- “Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data”
eTOX, Pinto Gil Kevin, University Pompeu Fabra

44- “Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium”
HARMONY, D’Agostino Mattia, University of Turin

45- “Altering disease course before symptom onset: the European Prevention of Alzheimer’s Dementia (EPAD) project (WP4)”
EPAD, Gheorghe Delia, University of Oxford

46- “COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance”
COMBACTE-NET, Kostyanev Tomislav, University of Antwerp

47- “Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)“
COMBACTE-CARE and COMBACTE-NET, Kostyanev Tomislav, University of Antwerp

48- “Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort”
EU-AIMS, Ahmad Jumana, King’s College London

49- “Novel peptide vaccines against Rift valley fever virus”
ZAPI, Gutjahr Benjamin, Friedrich-Loeffler-Institut FLI

50- “Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer’s Disease across the spectrum”
ROADMAP, Ly Amanda, University of Edinburgh

51- “Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder”
EU-AIMS, Garces Pilar, Roche

52- “Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso”
EBOVAC2, Houreratou Barry, Centre MURAZ

53- “A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals”
EQIPD, Vollert Jan, Imperial College London

54- “A Highly Productive Semi-Automated High Throughput Purification Process”
ELF, Levy Laura Mariana, Taros
ELF, Hristeva Stanimira, Taros

56- “Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study”
EBOVAC & EBOPLUS, Santoro Francesco, University of Siena

57- “Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine”
VSV-EBOVAC, VSV-EBOPLUS, Santoro Francesco, University of Siena

New clinical and regulatory paradigms

58- “What is responsible antibiotic use? Towards a global definition”
DRIVE-AB, Monnier Annelie, Radboud University Medical Center & Hasselt University

59- “The added value of quantitative amyloid PET in determining Alzheimer’s Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study”
AMYPAD, Lopes Alves Isadora, VU Medical Center Amsterdam

60- “Towards an adaptive mindset”
ADAPT SMART, Rohou Solange, Astrazeneca

61- “Regulatory and HTA considerations for disease-modifying drugs in Alzheimer’s disease”
ROADMAP, O’Rourke Diana, National Institute for Health and Care Excellence (NICE)

62- “Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited”
COMBACTE, Feifel Jan, Ulm University

63- “European Prevention of Alzheimer’s Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials”
EPAD, Vermunt Lisa, VU University Medical Center

64- “Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals”
iPIE, Wilkinson John, University of York

65- “Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer’s Disease”
ROADMAP, Dekker Marieke, Medicines Evaluation Board (MEB-CBG)

66- “IMI-PROTECT and benefit risk assessment”
PROTECT, Waddingham Edward, Imperial College London

67- “Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone”
EBOVAC, Baiden Frank, London School of Hygiene and Tropical Medicine
Patient engagement along the value chain

- 68 - “Characterising and appraising patient preference exploration and elicitation methods”  
   PREFER, Whichello Chiara, Erasmus University Rotterdam

- 69 - “Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics”  
   RESCUE, Wildenbeest Joanne G, Wilhelmina Children’s Hospital, University Medical Center Utrecht

- 70 - “Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes”  
   PARADIGM, Pakarinen Chi, the Synergist

- 71 - “Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone”  
   EBOVAC1, Shona Lee, EBOVAC Salone, Social Science Team

- 72 - “Bridging the gap between intention and action - Lessons learned from INNODIA’s Patient Advisory Committee”  
   INNODIA, Soderberg Jeannette, JDRF